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Abstract 
The 12-kDa and 12.6-kDa FK506-binding proteins, FKBP12 and FKBP12.6, have been implicated in 
the binding to and the regulation of ryanodine receptors (RyRs) and inositol 1,4,5-trisphosphate 
receptors (IP3Rs), both tetrameric intracellular Ca
2+
-release channels. While the amino acid sequences 
responsible for FKBP12 binding to RyRs are conserved in IP3Rs, FKBP12 binding to IP3Rs has been 
questioned and could not be observed in various experimental models. Nevertheless, conservation of 
these residues in the different IP3R isoforms and during evolution suggested that they could harbour an 
important regulatory site critical for IP3R-channel function. Recently, it has become clear that in 
IP3Rs, this site was targeted by B-cell lymphoma 2 (Bcl-2) via its BH4 domain, thereby dampening 
IP3R-mediated Ca
2+
 flux and preventing pro-apoptotic Ca
2+
 signalling. Furthermore, vice versa, the 
presence of the corresponding site in RyRs implied that Bcl-2 proteins could associate with and 
regulate RyR channels. Recently, the existence of endogenous RyR/Bcl-2 complexes has been 
identified in primary hippocampal neurons. Like for IP3Rs, binding of Bcl-2 to RyRs also involved its 
BH4 domain and suppressed RyR-mediated Ca
2+
 release. We therefore propose that the originally 
identified FKBP12-binding site in IP3Rs is a region critical for controlling IP3R-mediated Ca
2+
 flux by 
recruiting Bcl-2 rather than FKBP12. Although we hypothesize that anti-apoptotic Bcl-2 proteins, but 
not FKBP12, are the main physiological inhibitors of IP3Rs, we cannot exclude that Bcl-2 could help 
engaging FKBP12 (or other FKBP isoforms) to the IP3R, potentially via calcineurin.  
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Introduction 
Intracellular Ca
2+
 signalling regulates a variety of cellular processes [1]. A major organelle involved in 
the generation of these Ca
2+
 signals is the endoplasmic reticulum (ER), which not only is responsible 
for protein folding but also function as the main intracellular Ca
2+
 store [2]. The ER harbours two 
major protein families responsible for mediating Ca
2+
 release from the ER: the inositol 1,4,5-
trisphosphate receptors (IP3Rs [3]) and the ryanodine receptors (RyRs [4]). In short, three isoforms are 
known to exist for each intracellular Ca
2+
-release channel, which show a differential distribution 
among tissues [5, 6]. In this way, IP3Rs are ubiquitously expressed (at least one isoform in every cell), 
whereas high RyR expression is restricted to excitable and more specialized cells such as skeletal 
muscle (RyR1), cardiac muscle (RyR2), pancreas acinar cells (RyR1 and RyR2) and neurons (all 
isoforms). Both IP3Rs and RyRs function as a tetrameric unit inserted via a C-terminal Ca
2+
-permeable 
channel domain into the ER membrane. Due to their size (IP3R>300 kDa and RyR>500kDa for their 
monomers), this organization results in a large cytosolic regulatory domain and a relatively small 
luminal domain. This cytosolic regulatory part of both channels is the target of several common 
regulatory mechanisms. Some of these regulators are cellular factors (Ca
2+
, ATP, and Mg
2+
), protein 
kinases and associated proteins [5, 6]. IP3Rs and RyRs not only share functional and regulatory 
similarities, but also display structural similarities, e.g. at the level of their N-terminal domains and 
their distance to the transmembrane domains [7, 8]. 
 
The 12-kDa FK506-binding protein (FKBP12) and the 12.6-kDa FK506-binding protein (FKBP12.6) 
as critical regulators of RyR channels 
An important regulatory protein associated with the RyRs is FKBP12 [9]. FKBPs together with 
cyclophilins (CPs) form the immunophilin family, characterized by its targeting by 
immunosuppressive drugs, including rapamycin and FK506 for FKBPs and cyclosporine A (CsA) for 
CPs [10, 11]. Complex formation of these drugs with FKBPs and CPs impacts phosphorylation events 
in the cell by targeting and inhibiting kinases and phosphatases. As such, the complex FK506/FKBP12 
and the complex CsA/CP inhibit the Ca
2+
/calmodulin-dependent phosphatase, calcineurin/PP2B [12], 
while the complex rapamycin/FKBP12 inhibits the mammalian target of rapamycin complex 1 [13, 
14].  Besides this pharmacological signature, immunophilins display a cis/trans peptidylprolyl 
isomerase activity [15, 16].  
FKBPs also form complexes with Ca
2+
 release channels, namely the RyRs [9]. Marks and co-workers 
reported the physiological and FK506-sensitive association of four FKBP12 molecules with the 
tetrameric RyR channel present in sarcoplasmic reticulum of skeletal muscle cells [17]. FKBP12-
stripped RyR channels displayed increased Ca
2+
 flux and were sensitized to agonists like caffeine [18]. 
At the single-channel level, FKBP12 binding to RyR1 prevented the occurrence of sub-conductance 
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states, thereby stabilizing the channel in two conformations: (i) the closed state and (ii) the fully open 
state [19].  
RyR/FKBP12-complex formation not only occurs in the context of the skeletal muscle, but also in 
cardiac muscle [20]. The immunophilin responsible for binding RyRs in the heart seemed a different 
FKBP isoform, namely FKBP12.6. However, this may be species dependent, since rat RyR2 mainly 
associated with FKBP12.6 while rabbit RyR2 exclusively associated with FKBP12 [21]. Single-
channel analysis of cardiac RyR channels also revealed that rapamycin disrupted the binding of 
FKBP12.6 to the cardiac RyR protein [22]. FKBP12/FKBP12.6 not only promoted the coordinated 
Ca
2+
 flux among the four subunits of each RyR channel but also “coupled gating” [23]. This means 
that FKBP12/FKBP12.6 caused neighbouring or clustered RyR channels to function as a single unit 
that quasi-simultaneously open and close. Particularly, in the heart, these properties appear to be 
important to prevent aberrant and thus arrhythmic Ca
2+
 leakage during diastole and to facilitate proper 
Ca
2+
 flux during systole [24]. Besides immunosuppressive drugs, hyperphosphorylation of RyR2 at 
Ser2809 by protein kinase A (PKA) during heart failure or chronic elevated adrenergic stimulation has 
been reported to disrupt RyR2/FKBP12.6 complexes [25]. Yet, the position of the PKA-
phosphorylated residue in RyR2 (Ser2808 versus Ser2030) and the relevance of PKA-mediated 
phosphorylation of RyR2 during heart failure have been questioned [26, 27], while PKA-mediated 
phosphorylation of RyR2 at Ser2808 did not dissociate FKBP12.6 from RyR2 [28]. Also, FKBP12.6-
deficient mice have been reported to display exercise-induced sudden death due to aberrant RyR2 
function [29]. In contrast to this, loss of FKBP12.6 has been reported to neither alter the functional 
properties of the cardiac RyR2 nor the tendency for spontaneous Ca
2+
-release events to occur [30]. As 
a consequence, FKBP12.6-knockout mice were not more vulnerable to stress-induced ventricular 
arrhythmias [30]. Nevertheless, defective RyR2/FKBP12.6-complex formation has also been observed 
in RyR2 channels containing mutations that are associated with catecholaminergic polymorphic 
ventricular tachycardia (CPVT) [31]. Proper FKBP12.6 recruitment to and normal Ca
2+
 flux through 
these defective CPVT-mutated RyR2 channels could be pharmacologically restored using JTV519 
[32], a benzothiazepine derivative which stabilizes RyR2/FKBP12.6 complexes. In addition to 
phosphorylation events, oxidizing reagents (like H2O2 and diamide) or pathological conditions 
associated with increased reactive oxygen species production have been implicated to negatively 
impact the binding of FKBP12.6 to oxidized RyR2 [33, 34]. Importantly, JTV519 could not restore 
this loss of FKBP12.6 binding to RyR2 under oxidizing conditions [33]. Also, other reports indicated 
that the anti-arrhythmic properties of JTV519 suppressed spontaneous Ca
2+
-release events by CPVT-
linked mutant RyR2 channels independently of FKBP12.6 [35]. Finally, it is important to note that 
different alternative models have been proposed for RyR2 modulation by FKBP12.6, including its 
ability to counteract the activation of RyR2 by FKBP12 [36].  
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Finally, also RyR3 channels form complexes with FKBP12 and FKPB12.6 that are sensitive to 
exposure to FK506 [37, 38]. FKBP12 and FKBP12.6 bound the RyR3 protein with similar 
efficiencies. The formation of these complexes appeared regulated by Ca
2+
 and Mg
2+
, but not by cyclic 
ADP ribose. The binding of FKBP12 to RyR3 prevented the occurrence of spontaneous Ca
2+
-release 
events (Ca
2+
 sparks), because overexpression of FKBP12 prominently reduced the number of 
spontaneous sparks in RyR3-expressing HEK293 cells [39]. 
 
The binding site of FKBP12/FKBP12.6 on RyR isoforms 
Several groups have identified a potential FKBP12-binding site in the centre of the RyR-channel 
complex at a dipeptidylprolyl motif, in which the first amino acid is hydrophobic (Fig. 1). In RyR1, 
Val2461 preceding Pro2462 was identified as a key residue for the binding of FKBP12 [40]. Val2461-
mutated RyR1 channels, defective in FKBP12 binding, displayed altered single-channel properties, 
including an increased open probability at low cytosolic [Ca
2+
]. Furthermore, replacing Val2461 into 
Ile in the RyR1 sequence, resembling the corresponding residue in the RyR2 sequence, resulted in 
reduced FKBP12 binding and in increased FKBP12.6 binding. RyR1
Val2461Ile
 expressed in HEK293 
cells that contain endogenous FKBP12, but not FKBP12.6, displayed altered single-channel properties 
that could be corrected by adding FKBP12.6.  
Also in RyR3, a central valine-proline motif was essential for FKBP12 binding (Fig. 1). Mutating 
Val2322 into Asp in mink RyR3 reduced FKBP12 binding, increased spontaneous Ca
2+
 puffs and 
increased sensitivity towards opening in response to caffeine [39]. 
In RyR2, the situation is more complex. Originally, it was proposed that the FKBP12.6-binding site is 
located in the central RyR2 domain (a.a. 2361-2496), which contains a Ile2427/Pro2428 pair (Fig. 1). 
In yeast two-hybrid assays, the binding of FKBP12.6 to the RyR2 fragment was disrupted by 
rapamycin [25]. Yet, the molecular determinants underlying FKBP12.6 binding to RyR2 have been 
debated [41]. For instance, an N-terminal fragment containing a.a. 305-1937 of RyR2 was found to be 
responsible for FKBP12.6 binding [42]. Using elegant cryo-EM analysis of GFP-inserted RyR2 
channels and FRET-based studies and in agreement with previous reports of his group, Chen and co-
workers convincingly showed that FKBP12.6 associates with the N-terminal portion of the RyR2 
channels with a prominent role for two regions: a first region between a.a. 305 and 784 and a second 
region between a.a. 1815 and 1855. Interestingly, both regions are adjacent in the 3D RyR2 structure 
[43].  
Very recently, the high-resolution structures of the RyR1 channel have been published [44-46]. From 
these structures, it appears that FKBP12 binding to RyR1 occurs via a site located in the N-terminal 
part of the RyR1 channel [45]. Hence, this analysis implies that not only RyR2 but probably also the 
other RyR isoforms harbour an FKBP12/FKBP12.6-binding site in their N-terminal region. 
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A potential FKBP12-binding site is conserved in the central regulatory domains of IP3Rs 
Besides RyRs, IP3Rs, another class of intracellular Ca
2+
-release channels, have been proposed by 
Snyder and co-workers to serve as targets for FKBP12, inhibiting the channel [47] (Fig. 2, model A). 
FKBP12 co-purified with IP3Rs from rat cerebellar membranes in an FK506-dependent manner. 
FKBP12-stripped IP3R increased the basal Ca
2+
-leak from microsomal preparations and sensitized 
IP3Rs towards activation by IP3. FKBP12 did not function by itself but rather served as an adaptor 
protein responsible for linking calcineurin to the IP3R [48]. Disrupting the binding of FKBP12 to the 
IP3R also resulted in the loss of calcineurin recruitment to the IP3R and loss of calcineurin-dependent 
dephosphorylation of the IP3R channel. Hence, it was proposed that Ca
2+
 release through IP3Rs could 
locally activate calcineurin and dephosphorylate IP3Rs, thereby reducing its Ca
2+
-flux properties, 
creating a negative feedback loop that is controlled by Ca
2+
 [48]. In contrast, inhibition of calcineurin 
by FK506 will abolish this negative feedback loop, thereby favouring phosphorylation of IP3R 
channels (e.g. via PKA-dependent mechanisms) and enhancing IP3R function and IP3-induced Ca
2+
 
release. At the molecular level, an FKBP12-binding site was identified in the central, modulatory 
domain of the IP3R1 channel using a yeast two-hybrid assay [49]. In this region (a.a. 1349-1460), 
Pro1401 was critical for interaction with FKBP12, because its mutation abolished FKBP12 binding, 
while other Pro residues in the fragment were not important. The authors proposed that Pro1401 and 
the preceding Leu1400 residue served as an FK506-mimicking structure. Interestingly, the proposed 
binding site was conserved among the three different IP3R isoforms (Fig. 1) and correlated with the 
sequences identified in RyRs to act as an FKBP12-binding site. 
However, in contrast to these reports by Snyder and co-workers, other teams, including our laboratory, 
could neither detect IP3R/FKBP12-complex formation [38, 50] nor alterations in IP3R-mediated Ca
2+
 
fluxes in response to FKBP12 overexpression [51], purified FKBP12 addition [37] or FK506 treatment 
[37, 52]. In our team, we have employed different experimental approaches combining biochemical 
and functional techniques, but none of these assays indicated that IP3Rs could form complexes with 
FKBP12 or could be regulated by these proteins [37, 38, 52], while the same approaches could 
confirm FKBP12 binding to and regulation of RyR isoforms [37, 38].  Importantly, the amino acid 
sequence of the IP3R1 corresponding to the proposed FKBP12-binding site placed in the context of the 
full-length RyR3 was able to bind FKBP12, indicating that the primary IP3R1 sequence displayed 
FKBP12-binding properties in the proper structural environment of the RyR3 [38]. As such, it was 
postulated that the higher order structural organization of the leucylprolyl dipeptide motif was 
essential to serve as an FKBP12-binding site. Secondary structure predictions suggested that the 
structural micro-environment of the leucylprolyl motif in the IP3R was completely different than the 
one of the motif in the RyR, where it served as an “alpha-helical breaker” [38, 53]. 
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For a detailed discussion regarding the controversial role of FKBP12 for regulating IP3R channels, we 
would like to refer to a recent review [54]. In any case, while the regulation of RyR channels by 
FKBP12 proteins has been consistently observed by different labs, it is clear that IP3Rs are very poor 
targets of FKBP12 or that the interaction between IP3Rs and FKBP12, if any, is strongly dependent on 
the cellular context or cell types.  
 
The B-cell lymphoma 2 (Bcl-2) protein targets the FKBP12-binding site on IP3Rs and RyRs 
Strikingly, while the binding of FKBP12 to IP3Rs may be very weak or strongly context dependent, its 
proposed binding site seems anyway to be important, because i) the amino acid sequence stretch 
surrounding the leucylprolyl motif is conserved among the different IP3R isoforms and during 
evolution and ii) the corresponding motifs and surrounding amino acid sequences are present in the 
RyR isoforms and are responsible for FKBP12 and/or FKBP12.6 binding. A number of years ago, in 
collaboration with the laboratory of Clark Distelhorst, we could identify in mouse IP3R1 the binding 
site for the anti-apoptotic Bcl-2 protein [55]. Importantly, this region encompassed the leucylprolyl 
motif identified as a putative FKBP12-binding site [49] (Fig. 1).  
The Bcl-2-protein family consists of both anti- and pro-apoptotic family members and exerts its 
function through the presence of one to four Bcl-2 homology (BH) domains [56]. Anti-apoptotic Bcl-2 
family members usually contain four of these BH domains (Fig. 3). The BH1, 2 and 3 domains form a 
hydrophobic cleft, which scaffolds the BH3 domains of the pro-apoptotic Bcl-2-family members, 
thereby neutralizing their pro-apoptotic function [57]. The BH4 domain is essential for the anti-
apoptotic function of Bcl-2, since Bcl-2BH4 fails to act as an anti-apoptotic protein [58]. The BH4 
domain of Bcl-2, which can interact with several proteins [59, 60], was essential and sufficient to bind 
to IP3R1 by targeting a 20 amino acid region (a.a. 1389-1408) within its central, modulatory domain 
[59, 61] (Fig. 3). Binding of Bcl-2 or its BH4 domain to the IP3R channel dampened Ca
2+
 flux through 
the channel and protected the cells against apoptosis by suppressing excessive Ca
2+
 transfer from the 
ER to the mitochondria [59, 61]. Consistent with the fact that the amino acid stretch responsible for 
Bcl-2 recruitment to IP3R1 is conserved among the various IP3R isoforms (Fig. 1), the purified central, 
modulatory domains of IP3R2 and IP3R3 were also able to interact with full-length Bcl-2 as well as 
with its isolated BH4 domain region [62]. Interestingly, the functional implications of Bcl-2 binding to 
IP3R resemble the ones originally described for FKBP12 binding to IP3R, namely causing an inhibition 
of IP3R-mediated Ca
2+
 flux.  
In addition to this, it also became recently clear that in T cells and B-cell cancer cell models Bcl-2 not 
only binds directly to IP3Rs but also serves as a docking protein responsible for the recruitment of 
calcineurin and dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an inhibitor 
of protein phosphatase 1 (PP1) [63, 64] (Fig. 2, model B). DARPP-32 is activated by PKA and 
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deactivated by calcineurin. The formation of a complex between the IP3R, Bcl-2, DARPP-32 and 
calcineurin allows a delicate control of IP3-induced Ca
2+
 release. After T-cell stimulation IP3-induced 
Ca
2+
 release is therefore first increased by the PKA-mediated IP3R phosphorylation but subsequently 
repressed by the consecutive activation of calcineurin. This leads to the removal of DARPP-32-
mediated inhibition of PP1, allowing PP1 to dephosphorylate and inactivate the IP3R. As such, Bcl-2 
has therefore two ways to limit IP3R activity: i) via a direct inhibition in the central, modulatory 
domain, thereby negatively impacting the opening of the channel in response to IP3 binding, and ii) via 
a regulatory mechanism involving calcineurin and PP1, thereby limiting phosphorylation of the IP3R 
by PKA and preventing its hypersensitivity to IP3. This recent study using T cells and B-cell cancer 
cells underpins previous observations obtained from using neuronal tissues [65-67]. These studies 
showed that calcineurin can bind Bcl-2, thereby linking calcineurin to IP3Rs. IP3Rs/calcineurin 
complexes could be observed in hippocampal lysates from Bcl-2 wild-type but not of Bcl-2-knockout 
mice.  
 
Bcl-2 binding to RyRs 
Driven by the striking resemblance of the identified Bcl-2-binding site on the IP3R with an amino acid 
stretch present in the RyR sequence, we recently reported that Bcl-2 could also target RyRs [68]. 
Importantly, RyR/Bcl-2-protein complexes were identified in overexpression models and in rat 
hippocampal neurons [68]. It also became clear that Bcl-2 directly bound to RyRs via the same 
molecular determinant that involved interaction with IP3Rs: i) the central, modulatory domain of all 
three RyR isoforms was able to bind full-length Bcl-2; and ii) the BH4 domain of Bcl-2 was sufficient 
to bind purified RyR fragments (from all three RyR isoforms) (Fig. 3). Also, at the functional level, 
the impact of Bcl-2 on RyR function resembled its effect on IP3Rs, i.e. limiting Ca
2+
 release mediated 
by RyRs. In any case, it is clear that the RyR region corresponding to the Bcl-2-binding site in IP3R 
(i.e. 2448-2469 in rabbit RyR1; 2415-2436 in rabbit RyR2; 2309-2330 in mink RyR3) overlaps with 
the previously identified dipeptidylprolyl motif serving as the FKBP12/FKBP12.6 binding site (Fig. 
1). Hence, physiological complex formation between RyRs and Bcl-2 likely will depend on i) the 
relative expression/abundance of FKBP12 (or FKBP12.6) versus Bcl-2 in cell types and tissues, and ii) 
the affinity of FKBP12 (or FKBP12.6) and of Bcl-2 for binding to RyRs. 
 
Bcl-2 proteins as targets of immunophilins 
Clearly, Bcl-2 and its family members display functions that are unrelated to the regulation of 
apoptosis [69, 70]. Besides Bcl-2 proteins targeting and regulating IP3Rs and RyRs via a putative or 
real FKBP12-binding site, Bcl-2 might also recruit immunophilins to IP3Rs and RyRs, because Bcl-2 
can form complexes with FKBP38, another immunophilin-family member [71, 72]. FKBP38 may 
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target Bcl-2 to the mitochondria and inhibit apoptosis [72], although other reports have indicated that 
FKBP38 binding to Bcl-2 rather promotes apoptosis [73]. Interestingly, FKBP38 peptidylprolyl 
isomerase activity critically depends on complex formation with Ca
2+
/calmodulin [73]. It has been 
proposed that only the “active” Ca2+/calmodulin/FKBP38 complex can bind Bcl-2 [73], which is 
consistent with findings that a charge-sensitive loop within the catalytic domain of FKBP38 is 
responsible for Bcl-2 binding [74]. This provides an interesting link between Ca
2+
 signalling and Bcl-
2-protein function. FKBP38 interacts with Bcl-2 via its flexible loop (Fig. 3) and enhances its anti-
apoptotic properties at the level of the mitochondria, potentially by stabilizing its structure, improving 
its folding and/or preventing its degradation by proteolytic enzymes like caspase 3 [75, 76]. In 
addition, FKBP38 appears to counteract Jun N-terminal kinase (JNK)-dependent phosphorylation of 
Bcl-2, which is implicated in neutralizing its anti-apoptotic function [76]. Vice versa, JNK-dependent 
phosphorylation of Bcl-2 hampered complex formation with FKBP38 [76]. These findings indicate 
that Bcl-2 proteins can interact with immunophilins and thus may recruit immunophilins to other Bcl-2 
targets, like IP3Rs (Fig. 2, model C). Of note, it remains to be elucidated whether Bcl-2 can form 
complexes with FKBP12. In any case, the observed interaction of FKBP12 proteins with IP3Rs in 
some cellular models and conditions but not in others might therefore depend on the availability of 
Bcl-2, its presence in IP3R-protein complexes, and the nature of the other proteins in the complex (as 
e.g. calcineurin and DARPP-32). Indirect binding of FKBP12 to IP3Rs may thus occur via the Bcl-
2/calcineurin complex (Fig. 2, model D). This could explain results from previous studies showing 
that (bacterially expressed and purified) FKBP12 could not directly bind to IP3Rs. In addition, the 
isolation of intact ternary (IP3R/Bcl-2/FKBP12) or of quaternary (IP3R/Bcl-2/calcineurin/FKBP12) 
complexes may be very challenging and is likely strongly dependent on the experimental conditions 
used (e.g. cell types, detergents, solubilisation steps, etc…) and on the endogenous activity of the key 
players in the complex (e.g. active versus non-active calcineurin). This may in part underlie the 
controversy about IP3R regulation by FKBP12 proteins [54]. 
 
Conclusions 
RyRs have been identified as important targets of FKBP12 and FKBP12.6, members of the 
immunophilin family. A central dipeptidylprolyl motif was identified as the binding site for these 
proteins. This motif was embedded in a region that not only is conserved among all three RyR 
isoforms but also among the different IP3R isoforms. As a consequence, also IP3R channels were 
proposed to be targeted and regulated by FKBP12 by serving as an adaptor protein for calcineurin, 
leading to IP3Rs dephosphorylation and thus limiting its activity. Strikingly, while the sequence 
appeared to be strongly conserved in IP3Rs, its relevance for binding FKBP12 was subsequently 
questioned. Recent work however can explain the conservation of this site between the different IP3R 
isoforms, revealing an important role in recruiting Bcl-2. Binding of Bcl-2 to IP3Rs dampened its 
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Ca
2+
-flux properties via a direct interaction as well as via the recruitment of calcineurin and DARPP-
32. Thus, we hypothesize that Bcl-2 actually fulfils the role originally attributed to FKBP12 in the 
regulation of IP3R channels. Importantly, since the site is shared among IP3Rs and RyRs, Bcl-2 has 
been shown to interact with RyRs and to inhibit their Ca
2+
-release activity. Hence, FKBP12 and Bcl-2 
proteins may both serve as important regulatory proteins controlling IP3R and RyR function. Yet, 
while the role of FKBP12 proteins may be limited to RyRs, Bcl-2 proteins may impact both IP3Rs and 
RyRs. In addition to this, Bcl-2 proteins may serve as general adaptors, recruiting calcineurin/DARPP-
32 and/or immunophilins to IP3Rs and potentially RyRs. This definitely adds a further level of 
complexity to the fine-tuning of IP3Rs and RyRs by immunophilins and Bcl-2. 
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Figure legends 
Figure 1. The proposed FKBP12- and Bcl-2-binding sites in the different human IP3R and RyR 
isoforms. The conserved X-Pro motif (X=Leu, Ile or Val) proposed as the FKBP12 (or FKBP12.6)-
binding site (red) and the conserved stretch of 20 amino acids identified as the Bcl-2-binding site 
(blue) in the central, modulatory domain of the different IP3R and RyR isoforms have been indicated. 
 
Figure 2. Possible models for the regulation of IP3R channels by FKBP12 and Bcl-2 proteins, 
including their role as linker proteins recruiting calcineurin. Model A is based on the work of 
Snyder and co-workers [47] proposing that FKBP12 binds and inhibits IP3Rs and link calcineurin to 
IP3Rs. Calcineurin-mediated dephosphorylation of IP3Rs would participate in suppressing IP3R 
activity. Model B is based on the work of Distelhorst and co-workers [63] showing that Bcl-2 binds 
and inhibits IP3Rs, thereby recruiting calcineurin and DARPP-32, a PKA-regulated inhibitor of protein 
phosphatase 1 (PP1). Model C is a hypothetical tripartite complex in which, in analogy with Bcl-2’s 
ability to bind FKBP38, it is proposed that Bcl-2 might bind FKBP12 and link it to IP3Rs. Model D is 
a hypothetical complex based on model B but in which additionally FKBP12 participate in the 
complex by binding to calcineurin. 
 
Figure 3. Linear representation of the Bcl-2 structure and its four BH domains. The anti-
apoptotic function of Bcl-2 is executed by the hydrophobic cleft formed by the BH3, BH1 and BH2 
domains, scaffolding and neutralizing pro-apoptotic BH3-only proteins and multi-domain Bax/Bak 
proteins. The additional presence of the BH4 domain is needed for Bcl-2’s anti-apoptotic function. Via 
its BH4 domain, Bcl-2 interacts with different Ca
2+
-transport systems, like the IP3R and the RyR and 
with Ca
2+
-dependent enzymes like calcineurin. Via its flexible loop, Bcl-2 binds the “active” 
Ca
2+
/calmodulin/FKBP38 complex via a Ca
2+
-dependent interaction. FKBP38 may prevent JNK-
dependent phosphorylation and/or caspase-3-mediated cleavage of Bcl-2.  
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